Oral Insulin Therapy to Prevent Progression of Immune-Mediated (Type 1) Diabetes
BERRIN ERGUN-LONGMIRE
Division of Pediatric Endocrinology, New York-Presbyterian Hospital, Weill Medical College of Cornell University, New York, New York
Search for more papers by this authorADINA ZEIDLER
Department of Medicine, University of Southern California, Los Angeles, California
Search for more papers by this authorROBERT RAPAPORT
Department of Pediatrics, Mount Sinai Medical Center, New York, New York
Search for more papers by this authorPHILIP RASKIN
University of Texas Southwestern Medical Center at Dallas, Dallas, Texas
Search for more papers by this authorDESMOND SCHATZ
Department of Pediatrics, University of Florida College of Medicine, Gainesville, Florida
Search for more papers by this authorALFONSO VARGAS
Department of Pediatrics, Louisiana State University Health Sciences Center, School of Medicine, New Orleans, Louisiana
Search for more papers by this authorSHERWYN SCHWARTZ
Diabetes and Glandular Disease Clinic, San Antonio, Texas
Search for more papers by this authorJOHN MALONE
University of South Florida Diabetes Center, St. Petersburg, Florida
Search for more papers by this authorJEFFREY KRISCHER
H. Lee Moffitt Cancer Center, University of South Florida, Tampa, Florida
Search for more papers by this authorCorresponding Author
NOEL K. MACLAREN
Bioseek Clinics, New York, New York 10022, USA
Address for correspondence: Noel K. Maclaren, M.D., Bioseek Clinics, 5 East 57th Street, 16th Floor, New York, NY 10022. Voice: 212-371-0658; fax: 212-371-3744. [email protected]Search for more papers by this authorBERRIN ERGUN-LONGMIRE
Division of Pediatric Endocrinology, New York-Presbyterian Hospital, Weill Medical College of Cornell University, New York, New York
Search for more papers by this authorADINA ZEIDLER
Department of Medicine, University of Southern California, Los Angeles, California
Search for more papers by this authorROBERT RAPAPORT
Department of Pediatrics, Mount Sinai Medical Center, New York, New York
Search for more papers by this authorPHILIP RASKIN
University of Texas Southwestern Medical Center at Dallas, Dallas, Texas
Search for more papers by this authorDESMOND SCHATZ
Department of Pediatrics, University of Florida College of Medicine, Gainesville, Florida
Search for more papers by this authorALFONSO VARGAS
Department of Pediatrics, Louisiana State University Health Sciences Center, School of Medicine, New Orleans, Louisiana
Search for more papers by this authorSHERWYN SCHWARTZ
Diabetes and Glandular Disease Clinic, San Antonio, Texas
Search for more papers by this authorJOHN MALONE
University of South Florida Diabetes Center, St. Petersburg, Florida
Search for more papers by this authorJEFFREY KRISCHER
H. Lee Moffitt Cancer Center, University of South Florida, Tampa, Florida
Search for more papers by this authorCorresponding Author
NOEL K. MACLAREN
Bioseek Clinics, New York, New York 10022, USA
Address for correspondence: Noel K. Maclaren, M.D., Bioseek Clinics, 5 East 57th Street, 16th Floor, New York, NY 10022. Voice: 212-371-0658; fax: 212-371-3744. [email protected]Search for more papers by this authorAbstract
Abstract: Repeated ingestion of insulin has been suggested as an immune tolerization therapy to prevent immune-mediated (type 1) diabetes. We performed a placebo-controlled, two-dose, oral insulin tolerance trial in newly diagnosed (< 2 years) diabetic patients who had required insulin replacement for less than 4 weeks and were found to have cytoplasmic islet cell autoantibodies (ICAs). No oral hypoglycemic agents were permitted during the trial. Endogenous insulin reserves were estimated at six-month intervals by plasma C-peptide responses to a mixed meal. Positive ICAs were found in 262 (31%) of the 846 patients screened. Of the 197 who agreed to participate, 187 could be followed for 6 to 36 months. Endogenous insulin retention was dependent upon initial stimulated C-peptide response, age at diabetes onset, and numbers of specific islet cell autoantibodies found. Oral insulin improved plasma C-peptide responses in patients diagnosed at ages greater than 20 years, best seen at the low (1 mg/day) over the high (10 mg/day) insulin dose (P= .003 and P= .01, respectively). In patients diagnosed before age 20 years, the 1 mg dose was ineffective, whereas the 10 mg dose actually accelerated C-peptide loss (P= .003). There were no adverse effects. If confirmed, these findings suggest that diabetic patients over age 20 years with ICA evidence of late-onset immune-mediated diabetes should be considered for oral insulin at 1 mg/day to better retain endogenous insulin secretion.
REFERENCES
- 1 Report of the Expert Committee on Diagnosis and Classification of Diabetes Mellitus. 1997. Diabetes Care 20: 1183–1196.
- 2 Kukreja, A. & N.K. Maclaren. 1999. The autoimmunity of immune mediated diabetes. J. Clin. Endocrinol. Metab. 84: 4371–4378.
- 3 Maclaren, N.K. & A. Kukreja. 2000. Type 1 diabetes. In The Metabolic and Molecular Bases of Inherited Disease. William S. Sly, Ed.: 1471–1478. McGraw-Hill. St. Louis.
- 4 Saudek, C. 1995. Non-ophthalmologic findings of the diabetes control and complications trial. Surv. Ophthalmol. 40: 157–162.
- 5 Diabetes Control and Complications Trial Research Group. 1998. Effect of intensive therapy on residual beta cell function in patients with Type-1 diabetes in the Diabetes Control and Complications Trial. Ann. Intern. Med. 128: 517–523.
- 6 Silverstein, J., N. Maclaren, W. Riley, et al. 1988. Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. N. Engl. J. Med. 319: 599–604.
- 7 Stiller, C.R., J. Dupre, M. Gent, et al. 1984. Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 223: 1362–1367.
- 8 Feutren, G., L. Papoz, R. Assan, et al. 1986. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of multi-center double-blind trial. Lancet 2: 119–124.
- 9 Kaufman, D.L., M. Clare-Salzler, J. Tian, et al. 1993. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 366: 69–72.
- 10 Muir, A., A. Peck, M. Clare-Salzler, et al. 1995. Insulin immunization of non-obese diabetic mice induces a protective insulitis characterized by diminished intra-islet interferon-gamma transcription. J. Clin. Invest. 95: 628–634.
- 11 Zhang, Z.J., L. Davidson, G. Eisenbarth, et al. 1991. Suppression of diabetes in non-obese diabetic mice by oral administration of porcine insulin. Proc. Natl. Acad. Sci. USA 88: 10252–10256.
- 12 Ramiya, V.K., M.S. Lan, C.H. Wasserfall, et al. 1997. Immunization therapies in the prevention of diabetes. J. Autoimmun. 10: 287–292.
- 13 DPT-1 Study Group. 1995. The Diabetes Prevention Trial-Type 1 diabetes (DPT-1): implementation of screening and staging of relatives. Transplant Proc. 27: 3377.
- 14 ENDIT Group. 2003. Intervening before the onset of type 1 diabetes: baseline data from the European Nicotinamide Diabetes Intervention Trial (ENDIT). Diabetologia 46: 339–346.
- 15 Diabetes Prevention Trial-Type 1 Diabetes Study Group. 2002. Effects of insulin in relatives of patients with type 1 diabetes mellitus. Diabetes prevention trial-type 1 diabetes study group. N. Engl. J. Med. 346: 1685–1691.
- 16 Chaillous, L., H. Lefevre, C. Thivolet, et al. 2000. Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabete Insuline Orale group. Lancet 356: 545–549.
- 17 Pozzilli, P., D. Pitocco, N. Visalli, et al. 2000. No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). Diabetologia 43: 1000–1004.
- 18 Riley, W.J., N.K. Maclaren, J. Krischer, et al. 1990. A prospective study of the development of diabetes in relatives of patients with insulin-dependent diabetes. N. Engl. J. Med. 323: 1167–1172.
- 19 Vardi, P., L. Crisa & R.A. Jackson. 1991. Predictive value of intravenous glucose tolerance test insulin secretion less than or greater than the first percentile in islet cell antibody positive relatives of type 1 (insulin-dependent) diabetic patients. Diabetologia 34: 93–102.
- 20 Maclaren, N., M. Lan, R. Coutant, et al. 1999. Only multiple auto-antibodies to islet cells (ICA), insulin, GAD65, IA-2 and IA-2β predict immune-mediated (Type 1) diabetes in relatives. J. Autoimmun. 12: 279–287.
- 21 Hempe, J.M., J.N. Granger & R.D. Craver. 1997. Capillary iso-electric focusing of hemoglobin variants in the pediatric clinical laboratory. Electrophoresis 18: 1785–1795.
- 22 Coutant, R., A. Zeidler, R. Rappaport, et al. 1998. Oral insulin therapy in newly diagnosed immune mediated (type-1) diabetes. Preliminary analysis of a randomized double blind placebo controlled study [abstract]. Diabetes 47(Suppl. 1): A97.
- 23 Aviles-Santa, L., N. Maclaren & P. Raskin. 2004. The relationship between immune-mediated Type 1 diabetes mellitus and ethnicity. J. Diabetes Complications 18: 1–9.
- 24 Maruyama, T., A. Shimada, A. Kanatsuka, et al. 2003. Multicenter prevention trial of slowly progressive type 1 diabetes with small dose of insulin (the Tokyo study): preliminary report. Ann. N. Y. Acad. Sci. 1005: 362–369.
- 25 Weiner, H.L. 1997. Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol. Today 18: 335–343.
- 26 Ramiya, V.K., X.Z. Shang, P.G. Pharis, et al. 1996. Antigen based therapies to prevent diabetes in NOD mice. J. Autoimmun. 9: 349–356.
- 27 Ramiya, V.K., X.Z. Shang, C.H. Wasserfall, et al. 1997. Effect of oral and intravenous insulin and glutamic acid decarboxylase in NOD mice. Autoimmunity 26: 139–151.
- 28 Schatz, D., D. Cuthbertson, M. Atkinson, et al. 2004. Preservation of C-peptide secretion in subjects at high risk of developing type 1 diabetes mellitus—a new surrogate measure of non-progression? Pediatr. Diabetes 5: 72–79.